Opens in a new tab or window In patients with moderate to severe knee osteoarthritis that didn't respond to conservative treatments, quality-of-life and pain scores improved by 87% and 71% ...
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its ...